MapLight Therapeutics (MPLT) Earnings Analysis

MapLight Therapeutics (MPLT) next reports earnings on 2026-09-18, consensus EPS -1.32414 USD. Last quarter (2026-06-25) it missed with EPS -1.34 USD vs -0.91 USD est (-47.3%). It has beaten estimates in 0/3 recent quarters (0%). Trailing P/E -7.71.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MPLT next report earnings?

Next earnings date2026-09-18
Consensus EPS estimate-1.32414 USD
Revenue estimaten/a

MPLT earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-06-25-1.34 USD-0.91 USD-47.3%Miss
2026-05-14-1.34 USD-0.962 USD-39.3%Miss
2025-12-04-37.18 USD-1.72 USD-2061.6%Miss

Beat rate: 0/3 (0%) over reported quarters with consensus data.

MPLT valuation and analyst view

Trailing P/E-7.71
Trailing EPS-4.40579 USD
Price / book4.00
Dividend yield0.00%
Market cap0.03B
Analyst consensusBuy (5 buy / 0 hold / 0 sell)
Avg price target44.56 USD

Related research pages

Frequently asked questions

When is MapLight Therapeutics (MPLT)'s next earnings date?

MapLight Therapeutics is next scheduled to report on 2026-09-18, with a consensus EPS estimate of -1.32414 USD.

Did MPLT beat earnings last quarter?

In its 2026-06-25 report, MPLT posted EPS of -1.34 USD versus a -0.91 USD estimate — a miss of 47.3%.

What is MPLT's earnings track record?

Over the last 3 reported quarters with consensus data, MPLT beat estimates 0 times (0%).

What is MPLT's current P/E ratio and EPS?

MPLT trades at a trailing P/E of -7.71 on trailing EPS of -4.405791995333235 USD.

What do analysts rate MPLT?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 44.56 USD.